Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global Radiotherapy Market - Industry Trends and Forecast To 2027

Published by Data Bridge Market Research Private Limited Product code 961959
Published Content info 479 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Radiotherapy Market - Industry Trends and Forecast To 2027
Published: August 1, 2020 Content info: 479 Pages
Description

Global radiotherapy market is projected to register a CAGR of 5.7% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.

Market Segmentation:

Global Radiotherapy Market, By Type (External-Beam Radiation Therapy, Internal Radiation Therapy, Systemic Radiotherapy/Radiopharmaceuticals and Others), Product (External Beam Radiotherapy, Internal Radiotherapy Products, Radiotherapy Software and Others), Application (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Lymphoma, Liver Cancer, Thyroid Cancer, Brain Cancer, Cervical Cancer, Spine Cancer and Others), End User (Hospitals, Radiation Therapy Centers, Specialty Clinics and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (U.S., Canada & Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Belgium, Russia, Turkey, Ukraine, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Chile, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the global radiotherapy market are:

Increasing cases of cancer disease across the word

Technology advancement in the radiotherapy treatment

Market Players:

The key market players for global radiotherapy market are listed below:

Varian Medical Systems, Inc.

ProTom International

Mevion Medical Systems

VIEWRAY TECHNOLOGIES, INC. (a subsidiary of ViewRay)

Siemens Healthcare GmbH

Elekta AB

Accuray Incorporated

IBA Worldwide

Eckert & Ziegler BEBIG

RaySearch Laboratories

Brainlab AG

Koninklijke Philips N.V.

GE Healthcare

Hitachi, Ltd.

Advanced Accelerator Applications (a subsidiary of Novartis AG)

Provision Healthcare.

Nordion (Canada) Inc.

Sumitomo Heavy Industries, Ltd.

CIVCO Radiotherapy (a subsidiary of Roper Technologies)

Isoray Inc

Nordion (Canada) Inc.

Sumitomo Heavy Industries, Ltd.

CIVCO Radiotherapy (A Subsidiary of Roper Technologies)

Isoray Inc

Table of Contents

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL RADIOTHERAPY MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 TYPE LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 DBMR MARKET POSITION GRID
  • 2.10 MARKET APPLICATION COVERAGE GRID
  • 2.11 VENDOR SHARE ANALYSIS
  • 2.12 SECONDARY SOURCES
  • 2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 GLOBAL RADIOTHERAPY MARKET, MARKET SHARE ANALYSIS
    • 4.1.1 MARKET SHARE ANALYSIS: GLOBAL
    • 4.1.2 MARKET SHARE ANALYSIS: NORTH AMERICA
      • 4.1.2.1 MARKET SHARE ANALYSIS: U.S.
      • 4.1.2.2 MARKET SHARE ANALYSIS: CANADA
      • 4.1.2.3 MARKET SHARE ANALYSIS: MEXICO
    • 4.1.3 MARKET SHARE ANALYSIS: EUROPE
      • 4.1.3.1 MARKET SHARE ANALYSIS: GERMANY
      • 4.1.3.2 MARKET SHARE ANALYSIS: FRANCE
      • 4.1.3.3 MARKET SHARE ANALYSIS: ITALY
      • 4.1.3.4 MARKET SHARE ANALYSIS: U.K.
      • 4.1.3.5 MARKET SHARE ANALYSIS: SPAIN
      • 4.1.3.6 MARKET SHARE ANALYSIS: RUSSIA
      • 4.1.3.7 MARKET SHARE ANALYSIS: NETHERLANDS
      • 4.1.3.8 MARKET SHARE ANALYSIS: SWITZERLAND
      • 4.1.3.9 MARKET SHARE ANALYSIS: BELGIUM
      • 4.1.3.10 MARKET SHARE ANALYSIS: TURKEY
      • 4.1.3.11 MARKET SHARE ANALYSIS: UKRAINE
    • 4.1.4 MARKET SHARE ANALYSIS: ASIA-PACIFIC
      • 4.1.4.1 MARKET SHARE ANALYSIS: CHINA
      • 4.1.4.2 MARKET SHARE ANALYSIS: JAPAN
      • 4.1.4.3 MARKET SHARE ANALYSIS: INDIA
      • 4.1.4.4 MARKET SHARE ANALYSIS: AUSTRALIA
      • 4.1.4.5 MARKET SHARE ANALYSIS: SOUTH KOREA
      • 4.1.4.6 MARKET SHARE ANALYSIS: INDONESIA
      • 4.1.4.7 MARKET SHARE ANALYSIS: THAILAND
      • 4.1.4.8 MARKET SHARE ANALYSIS: SINGAPORE
      • 4.1.4.9 MARKET SHARE ANALYSIS: MALAYSIA
      • 4.1.4.10 MARKET SHARE ANALYSIS: PHILIPPINES
    • 4.1.5 MARKET SHARE ANALYSIS: SOUTH AMERICA
      • 4.1.5.1 MARKET SHARE ANALYSIS: BRAZIL
      • 4.1.5.2 MARKET SHARE ANALYSIS: ARGENTINA
      • 4.1.5.3 MARKET SHARE ANALYSIS: CHILE
    • 4.1.6 MARKET SHARE ANALYSIS: MIDDLE EAST AND AFRICA
      • 4.1.6.1 MARKET SHARE ANALYSIS: SOUTH AFRICA
      • 4.1.6.2 MARKET SHARE ANALYSIS: SAUDI ARABIA
      • 4.1.6.3 MARKET SHARE ANALYSIS: UAE
      • 4.1.6.4 MARKET SHARE ANALYSIS: EGYPT
      • 4.1.6.5 MARKET SHARE ANALYSIS: ISRAEL
  • 4.2 GLOBAL PROTON BEAM THERAPY IN RADIOTHERAPY MARKET, COMPANY LANDSCAPE
    • 4.2.1 COMPANY SHARE ANALYSIS: GLOBAL
    • 4.2.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
      • 4.2.2.1 COMPANY SHARE ANALYSIS: U.S.
      • 4.2.2.2 COMPANY SHARE ANALYSIS: CANADA
    • 4.2.3 COMPANY SHARE ANALYSIS: EUROPE
      • 4.2.3.1 COMPANY SHARE ANALYSIS: GERMANY
      • 4.2.3.2 COMPANY SHARE ANALYSIS: FRANCE
      • 4.2.3.3 COMPANY SHARE ANALYSIS: ITALY
      • 4.2.3.4 COMPANY SHARE ANALYSIS: U.K.
      • 4.2.3.5 COMPANY SHARE ANALYSIS: SPAIN
    • 4.2.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
      • 4.2.4.1 company share analysis: CHINA
      • 4.2.4.2 COMPANY SHARE ANALYSIS: JAPAN
      • 4.2.4.3 COMPANY SHARE ANALYSIS: INDIA
      • 4.2.4.4 COMPANY SHARE ANALYSIS: SOUTH KOREA
  • 4.3 GLOBAL BRACHYTHERAPY IN RADIOTHERAPY MARKET, COMPANY LANDSCAPE
    • 4.3.1 COMPANY SHARE ANALYSIS: GLOBAL
    • 4.3.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
      • 4.3.2.1 COMPANY SHARE ANALYSIS: U.S.
      • 4.3.2.2 COMPANY SHARE ANALYSIS: CANADA
    • 4.3.3 COMPANY SHARE ANALYSIS: EUROPE
      • 4.3.3.1 COMPANY SHARE ANALYSIS: GERMANY
      • 4.3.3.2 COMPANY SHARE ANALYSIS: FRANCE
      • 4.3.3.3 COMPANY SHARE ANALYSIS: ITALY
      • 4.3.3.4 COMPANY SHARE ANALYSIS: U.K.
      • 4.3.3.5 COMPANY SHARE ANALYSIS: SPAIN
    • 4.3.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
      • 4.3.4.1 COMPANY SHARE ANALYSIS: CHINA
      • 4.3.4.2 COMPANY SHARE ANALYSIS: JAPAN
      • 4.3.4.3 COMPANY SHARE ANALYSIS: INDIA
      • 4.3.4.4 COMPANY SHARE ANALYSIS: SOUTH KOREA
  • 4.4 GLOBAL IMAGE-GUIDED RADIATION THERAPY (IGRT) IN RADIOTHERAPY MARKET, COMPANY LANDSCAPE
    • 4.4.1 COMPANY SHARE ANALYSIS: GLOBAL
    • 4.4.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
      • 4.4.2.1 COMPANY SHARE ANALYSIS: U.S.
      • 4.4.2.2 COMPANY SHARE ANALYSIS: CANADA
    • 4.4.3 COMPANY SHARE ANALYSIS: EUROPE
      • 4.4.3.1 COMPANY SHARE ANALYSIS: GERMANY
      • 4.4.3.2 COMPANY SHARE ANALYSIS: FRANCE
      • 4.4.3.3 COMPANY SHARE ANALYSIS: ITALY
      • 4.4.3.4 COMPANY SHARE ANALYSIS: U.K.
      • 4.4.3.5 COMPANY SHARE ANALYSIS: SPAIN
    • 4.4.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
      • 4.4.4.1 COMPANY SHARE ANALYSIS: CHINA
      • 4.4.4.2 COMPANY SHARE ANALYSIS: JAPAN
      • 4.4.4.3 COMPANY SHARE ANALYSIS: INDIA
      • 4.4.4.4 COMPANY SHARE ANALYSIS: SOUTH KOREA
  • 4.5 GLOBAL STEREOTACTIC RADIATION THERAPY IN RADIOTHERAPY MARKET, COMPANY LANDSCAPE
    • 4.5.1 COMPANY SHARE ANALYSIS: GLOBAL
    • 4.5.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
      • 4.5.2.1 COMPANY SHARE ANALYSIS: U.S.
      • 4.5.2.2 COMPANY SHARE ANALYSIS: CANADA
    • 4.5.3 COMPANY SHARE ANALYSIS: EUROPE
      • 4.5.3.1 COMPANY SHARE ANALYSIS: GERMANY
      • 4.5.3.2 COMPANY SHARE ANALYSIS: FRANCE
      • 4.5.3.3 COMPANY SHARE ANALYSIS: ITALY
      • 4.5.3.4 COMPANY SHARE ANALYSIS: U.K.
      • 4.5.3.5 COMPANY SHARE ANALYSIS: SPAIN
    • 4.5.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
      • 4.5.4.1 COMPANY SHARE ANALYSIS: CHINA
      • 4.5.4.2 COMPANY SHARE ANALYSIS: JAPAN
      • 4.5.4.3 COMPANY SHARE ANALYSIS: INDIA
      • 4.5.4.4 COMPANY SHARE ANALYSIS: SOUTH KOREA

5 IMPACT OF COVID-19 ON GLOBAL RADIOTHERAPY MARKET

  • 5.1 IMPACT ANALYSIS ON DEMAND
  • 5.2 CONCLUSION

6 MARKET OVERVIEW

  • 6.1 DRIVERS
    • 6.1.1 GROWING PREVALENCE OF CANCER DISEASE
    • 6.1.2 NOVEL TECHNOLOGY IN RADIOTHERAPY FOR CANCER TREATMENT
    • 6.1.3 INCREASING ADOPTION OF RADIOTHERAPY DEVICES AND PROCEDURES
    • 6.1.4 RISING PREFERENCE FOR NON-SURGICAL PROCEDURES
  • 6.2 RESTRAINTS
    • 6.2.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
    • 6.2.2 COMPLEX NATURE OF RADIOTHERAPY
    • 6.2.3 HIGH COST OF RADIOTHERAPY PROCEDURES
  • 6.3 OPPORTUNITIES
    • 6.3.1 INCREASING HEALTHCARE EXPENDITURES FOR CANCER TREATMENTS
    • 6.3.2 GROWING GOVERNMENT INITIATIVES TOWARDS CANCER TREATMENT
    • 6.3.3 RISING PATIENTS AWARENESS TOWARDS CANCER TREATMENT
  • 6.4 CHALLENGES
    • 6.4.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF RADIOTHERAPY PRODUCTS
    • 6.4.2 RISK OF RADIATION EXPOSURE

7 GLOBAL RADIOTHERAPY MARKET, BY TYPE

  • 7.1 OVERVIEW
  • 7.2 EXTERNAL-BEAM RADIATION THERAPY
    • 7.2.1 IMAGE-GUIDED RADIATION THERAPY (IGRT)
    • 7.2.2 PROTON BEAM THERAPY
    • 7.2.3 STEREOTACTIC RADIATION THERAPY
    • 7.2.4 INTENSITY MODULATED RADIATION THERAPY (IMRT)
    • 7.2.5 THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY (3D-CRT)
    • 7.2.6 VOLUMETRIC MODULATED ARC THERAPY (VMAT)
    • 7.2.7 OTHERS
  • 7.3 INTERNAL RADIATION THERAPY
    • 7.3.1 BRACHYTHERAPY
    • 7.3.2 SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
    • 7.3.3 BRACHYTHERAPY
      • 7.3.3.1 HIGH DOSE BRACHYTHERAPY
      • 7.3.3.2 LOW DOSE BRACHYTHERAPY
  • 7.4 SYSTEMIC RADIOTHERAPY/ RADIOPHARMACEUTICALS
  • 7.5 OTHERS

8 GLOBAL RADIOTHERAPY MARKET, BY PRODUCT

  • 8.1 OVERVIEW
  • 8.2 EXTERNAL BEAM RADIOTHERAPY
    • 8.2.1 LINAC
    • 8.2.2 PROTON THERAPY
    • 8.2.3 CYBER KNIFE
    • 8.2.4 GAMMA KNIFE
    • 8.2.5 OTHERS
  • 8.3 INTERNAL RADIOTHERAPY PRODUCTS
    • 8.3.1 SEEDS
    • 8.3.2 AFTERLOADERS
    • 8.3.3 OTHERS
  • 8.4 RADIOTHERAPY SOFTWARE
    • 8.4.1 IMAGE GUIDING SOFTWARE
    • 8.4.2 TREATMENT PLANNING SOFTWARE
    • 8.4.3 PATIENT POSITIONING SOFTWARE
    • 8.4.4 DOSAGE PLANNING SOFTWARE
    • 8.4.5 OTHERS

9 GLOBAL RADIOTHERAPY MARKET, BY APPLICATION

  • 9.1 OVERVIEW
  • 9.2 BREAST CANCER
  • 9.3 LUNG CANCER
  • 9.4 PROSTATE CANCER
  • 9.5 COLORECTAL CANCER
  • 9.6 LYMPHOMA
  • 9.7 LIVER CANCER
  • 9.8 THYROID CANCER
  • 9.9 BRAIN CANCER
  • 9.10 CERVICAL CANCER
  • 9.11 SPINE CANCER
  • 9.12 OTHERS

10 GLOBAL RADIOTHERAPY MARKET, BY END USER

  • 10.1 OVERVIEW
  • 10.2 HOSPITALS
  • 10.3 RADIATION THERAPY CENTERS
  • 10.4 SPECIALTY CLINICS
  • 10.5 OTHERS

11 GLOBAL RADIOTHERAPY MARKET, BY DISTRIBUTION CHANNEL

  • 11.1 OVERVIEW
  • 11.2 DIRECT TENDER
  • 11.3 RETAIL SALES
  • 11.4 OTHERS

12 GLOBAL RADIOTHERAPY MARKET, BY GEOGRAPHY

  • 12.1 OVERVIEW
  • 12.2 NORTH AMERICA
    • 12.2.1 U.S.
    • 12.2.2 CANADA
    • 12.2.3 MEXICO
  • 12.3 EUROPE
    • 12.3.1 GERMANY
    • 12.3.2 FRANCE
    • 12.3.3 ITALY
    • 12.3.4 U.K.
    • 12.3.5 SPAIN
    • 12.3.6 RUSSIA
    • 12.3.7 NETHERLANDS
    • 12.3.8 SWITZERLAND
    • 12.3.9 BELGIUM
    • 12.3.10 TURKEY
    • 12.3.11 UKRAINE
    • 12.3.12 REST OF EUROPE
  • 12.4 ASIA-PACIFIC
    • 12.4.1 CHINA
    • 12.4.2 JAPAN
    • 12.4.3 INDIA
    • 12.4.4 AUSTRALIA
    • 12.4.5 SOUTH KOREA
    • 12.4.6 INDONESIA
    • 12.4.7 THAILAND
    • 12.4.8 SINGAPORE
    • 12.4.9 MALAYSIA
    • 12.4.10 PHILIPPINES
    • 12.4.11 REST OF ASIA-PACIFIC
  • 12.5 SOUTH AMERICA
    • 12.5.1 BRAZIL.
    • 12.5.2 ARGENTINA
    • 12.5.3 CHILE
    • 12.5.4 REST OF SOUTH AMERICA
  • 12.6 MIDDLE EAST AND AFRICA
    • 12.6.1 SOUTH AFRICA
    • 12.6.2 SAUDI ARABIA
    • 12.6.3 UAE
    • 12.6.4 EGYPT
    • 12.6.5 ISRAEL
    • 12.6.6 REST OF MIDDLE EAST AND AFRICA

13 GLOBAL RADIOTHERAPY MARKET, COMPANY LANDSCAPE

  • 13.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 13.3 COMPANY SHARE ANALYSIS: EUROPE
  • 13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

14 SWOT ANALYSIS

15 COMPANY PROFILE

  • 15.1 VARIAN MEDICAL SYSTEMS, INC.
    • 15.1.1 COMPANY SNAPSHOT
    • 15.1.2 REVENUE ANALYSIS
    • 15.1.3 COMPANY SHARE ANALYSIS
    • 15.1.4 PRODUCT PORTFOLIO
    • 15.1.5 RECENT DEVELOPMENTS
  • 15.2 ELEKTA AB
    • 15.2.1 COMPANY SNAPSHOT
    • 15.2.2 REVENUE ANALYSIS
    • 15.2.3 COMPANY SHARE ANALYSIS
    • 15.2.4 PRODUCT PORTFOLIO
    • 15.2.5 RECENT DEVELOPMENTS
  • 15.3 SIEMENS HEALTHCARE GMBH
    • 15.3.1 COMPANY SNAPSHOT
    • 15.3.2 REVENUE ANALYSIS
    • 15.3.3 COMPANY SHARE ANALYSIS
    • 15.3.4 PRODUCT PORTFOLIO
    • 15.3.5 RECENT DEVELOPMENTS
  • 15.4 GE HEALTHCARE
    • 15.4.1 COMPANY SNAPSHOT
    • 15.4.2 REVENUE ANALYSIS
    • 15.4.3 COMPANY SHARE ANALYSIS
    • 15.4.4 PRODUCT PORTFOLIO
    • 15.4.5 RECENT DEVELOPMENT
  • 15.5 ACCURAY INCORPORATED
    • 15.5.1 COMPANY SNAPSHOT
    • 15.5.2 REVENUE ANALYSIS
    • 15.5.3 COMPANY SHARE ANALYSIS
    • 15.5.4 PRODUCT PORTFOLIO
    • 15.5.5 RECENT DEVELOPMENT
  • 15.6 KONINKLIJKE PHILIPS N.V.
    • 15.6.1 COMPANY SNAPSHOT
    • 15.6.2 REVENUE ANALYSIS
    • 15.6.3 PRODUCT PORTFOLIO
    • 15.6.4 RECENT DEVELOPMENTS
  • 15.7 ADVANCED ACCELERATOR APPLICATIONS (A SUBSIDIARY OF NOVARTIS AG)
    • 15.7.1 COMPANY SNAPSHOT
    • 15.7.2 REVENUE ANALYSIS
    • 15.7.3 PRODUCT PORTFOLIO
    • 15.7.4 RECENT DEVELOPMENT
  • 15.8 BRAINLAB AG
    • 15.8.1 COMPANY SNAPSHOT
    • 15.8.2 PRODUCT PORTFOLIO
    • 15.8.3 RECENT DEVELOPMENT
  • 15.9 CIVCO RADIOTHERAPY (A SUBSIDIARY OF ROPER TECHNOLOGIES, INC.)
    • 15.9.1 COMPANY SNAPSHOT
    • 15.9.2 REVENUE ANALYSIS
    • 15.9.3 PRODUCT PORTFOLIO
    • 15.9.4 RECENT DEVELOPMENT
  • 15.10 ECKERT & ZIEGLER BEBIG
    • 15.10.1 COMPANY SNAPSHOT
    • 15.10.2 REVENUE ANALYSIS
    • 15.10.3 PRODUCT PORTFOLIO
    • 15.10.4 RECENT DEVELOPMENT
  • 15.11 HITACHI, LTD.
    • 15.11.1 COMPANY SNAPSHOT
    • 15.11.2 REVENUE ANALYSIS
    • 15.11.3 PRODUCT PORTFOLIO
    • 15.11.4 RECENT DEVELOPMENT
  • 15.12 IBA WORLDWIDE
    • 15.12.1 COMPANY SNAPSHOT
    • 15.12.2 REVENUE ANALYSIS
    • 15.12.3 PRODUCT PORTFOLIO
    • 15.12.4 RECENT DEVELOPMENT
  • 15.13 ISORAY INC.
    • 15.13.1 COMPANY SNAPSHOT
    • 15.13.2 REVENUE ANALYSIS
    • 15.13.3 PRODUCT PORTFOLIO
    • 15.13.4 RECENT DEVELOPMENT
  • 15.14 MEVION MEDICAL SYSTEMS
    • 15.14.1 COMPANY SNAPSHOT
    • 15.14.2 PRODUCT PORTFOLIO
    • 15.14.3 RECENT DEVELOPMENT
  • 15.15 NORDION (CANADA) INC.
    • 15.15.1 COMPANY SNAPSHOT
    • 15.15.2 PRODUCT PORTFOLIO
    • 15.15.3 RECENT DEVELOPMENT
  • 15.16 PROTOM INTERNATIONAL
    • 15.16.1 COMPANY SNAPSHOT
    • 15.16.2 PRODUCT PORTFOLIO
    • 15.16.3 RECENT DEVELOPMENT
  • 15.17 PROVISION HEALTHCARE
    • 15.17.1 COMPANY SNAPSHOT
    • 15.17.2 SOLUTION PORTFOLIO
    • 15.17.3 RECENT DEVELOPMENT
  • 15.18 RAYSEARCH LABORATORIES
    • 15.18.1 COMPANY SNAPSHOT
    • 15.18.2 REVENUE ANALYSIS
    • 15.18.3 PRODUCT PORTFOLIO
    • 15.18.4 RECENT DEVELOPMENT
  • 15.19 SUMITOMO HEAVY INDUSTRIES, LTD.
    • 15.19.1 COMPANY SNAPSHOT
    • 15.19.2 REVENUE ANALYSIS
    • 15.19.3 PRODUCT PORTFOLIO
    • 15.19.4 RECENT DEVELOPMENT
  • 15.20 VIEWRAY TECHNOLOGIES, INC. (A SUBSIDIARY OF VIEWRAY)
    • 15.20.1 COMPANY SNAPSHOT
    • 15.20.2 REVENUE ANALYSIS
    • 15.20.3 PRODUCT PORTFOLIO
    • 15.20.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

Back to Top